2017 American Transplant Congress
EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients.
Kidneys from hepatitis C-infected (HCV+) donors are underutilized in an era of severe organ shortage. In an effort to expand the donor pool, we evaluated…2017 American Transplant Congress
Reproducibility of the Cobas CMV Test (cobas CMV) and Clinical Concordance with the Cobas Ampliprep / Cobas TaqMan CMV Test (CAP/CTM CMV).
cobas CMV is a new, automated, high-throughput assay for use on the cobas 6800/8800 systems that quantifies CMV DNA in EDTA-plasma. It can be run…2017 American Transplant Congress
Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).
Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…2017 American Transplant Congress
Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.
Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of CMV infection. We purposed to evaluate the effect of valacyclovir…2017 American Transplant Congress
Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis.
Background: Regulatory trials assessing CMV drugs have utilized symptomatic CMV disease as the primary endpoint. However CMV disease occurs infrequently, CMV syndrome is nonspecific, and…2017 American Transplant Congress
Generation of Autologous CMV and EBV-Specific T-Cell Lines from Seronegative Patients for Cell Therapy of Opportunistic Infections Following Kidney Transplantation.
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations after kidney transplant are associated with substantial morbidity, especially in seronegative patients. Adoptive immunotherapy using virus-specific T cells…2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…2017 American Transplant Congress
Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients.
BACKGROUND: Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can…2017 American Transplant Congress
Impact of Ritonavir on Graft Function in Human Immunodeficiency Virus Infected Kidney Transplant Recipients.
Emory University Hospital, Atlanta, GA
Purpose: The purpose of this study was to determine the difference in 6 and 12 month graft function between patients with human immunodeficiency virus (HIV)…2017 American Transplant Congress
Tenofovir Use Is Not Associated with Reduced Bone Density or Fractures in Liver Transplant Recipients.
University of Minnesota, Minneapolis, MN
BackgroundTenofovir disproxil fumarate (TDF) and reduced bone density in the HIV population is well-documented. The effect of TDF use on bone density in patients who…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 14
- Next Page »